223 related articles for article (PubMed ID: 27472742)
1. Complement activation and effect of eculizumab in scleroderma renal crisis.
Devresse A; Aydin S; Le Quintrec M; Demoulin N; Stordeur P; Lambert C; Gastoldi S; Pirson Y; Jadoul M; Morelle J
Medicine (Baltimore); 2016 Jul; 95(30):e4459. PubMed ID: 27472742
[TBL] [Abstract][Full Text] [Related]
2. Studying the Role of C5-Inhibition Therapy in Scleroderma Renal Crisis-Induced Thrombotic Microangiopathy - A Review of Literature.
Farrukh L; Steen VD; Shapiro L; Mehta S
Semin Arthritis Rheum; 2023 Dec; 63():152256. PubMed ID: 37689027
[TBL] [Abstract][Full Text] [Related]
3. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
Laurence J; Mulvey JJ; Seshadri M; Racanelli A; Harp J; Schenck EJ; Zappetti D; Horn EM; Magro CM
Clin Immunol; 2020 Oct; 219():108555. PubMed ID: 32771488
[TBL] [Abstract][Full Text] [Related]
4. Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy.
Chua JS; Baelde HJ; Zandbergen M; Wilhelmus S; van Es LA; de Fijter JW; Bruijn JA; Bajema IM; Cohen D
J Am Soc Nephrol; 2015 Sep; 26(9):2239-47. PubMed ID: 25573909
[TBL] [Abstract][Full Text] [Related]
5. Effect of anti-C5 antibody on recuperation from ischemia/reperfusion-induced acute kidney injury.
Zilberman-Itskovich S; Abu-Hamad R; Stark M; Efrati S
Ren Fail; 2019 Nov; 41(1):967-975. PubMed ID: 31662004
[TBL] [Abstract][Full Text] [Related]
6. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option.
Román E; Mendizábal S; Jarque I; de la Rubia J; Sempere A; Morales E; Praga M; Ávila A; Górriz JL
Nefrologia; 2017; 37(5):478-491. PubMed ID: 28946961
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab deposits in vessel walls in thrombotic microangiopathy.
Cassol CA; Brodsky SV; Satoskar AA; Blissett AR; Cataland S; Nadasdy T
Kidney Int; 2019 Sep; 96(3):761-768. PubMed ID: 31345584
[TBL] [Abstract][Full Text] [Related]
8. Endothelial lesion and complement activation in patients with Scleroderma Renal Crisis.
Pérez NA; Morales MLA; Sánchez RS; Salas RMO; Puebla RÁF; Hernández ME
J Bras Nefrol; 2019; 41(4):580-584. PubMed ID: 30806445
[TBL] [Abstract][Full Text] [Related]
9. Management review of scleroderma renal crisis: An update with practical pointers.
Foocharoen C; Tonsawan P; Pongkulkiat P; Anutrakulchai S; Mahakkanukrauh A; Suwannaroj S
Mod Rheumatol; 2023 Jan; 33(1):12-20. PubMed ID: 35349704
[TBL] [Abstract][Full Text] [Related]
10. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition.
Sakamoto K; Imamura T; Osone S; Nishimura A; Nishida M; Ishida H; Hosoi H
Pediatr Transplant; 2015 Jun; 19(4):E97-100. PubMed ID: 25735190
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.
Hallstensen RF; Bergseth G; Foss S; Jæger S; Gedde-Dahl T; Holt J; Christiansen D; Lau C; Brekke OL; Armstrong E; Stefanovic V; Andersen JT; Sandlie I; Mollnes TE
Immunobiology; 2015 Apr; 220(4):452-9. PubMed ID: 25468724
[TBL] [Abstract][Full Text] [Related]
13. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
14. Therapy of scleroderma renal crisis: State of the art.
Zanatta E; Polito P; Favaro M; Larosa M; Marson P; Cozzi F; Doria A
Autoimmun Rev; 2018 Sep; 17(9):882-889. PubMed ID: 30005860
[TBL] [Abstract][Full Text] [Related]
15. Classical Complement Pathway Activation in the Kidneys of Women With Preeclampsia.
Penning M; Chua JS; van Kooten C; Zandbergen M; Buurma A; Schutte J; Bruijn JA; Khankin EV; Bloemenkamp K; Karumanchi SA; Baelde H
Hypertension; 2015 Jul; 66(1):117-25. PubMed ID: 25941343
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease.
Tran CL; Sethi S; Murray D; Cramer CH; Sas DJ; Willrich M; Smith RJ; Fervenza FC
Pediatr Nephrol; 2016 Apr; 31(4):683-7. PubMed ID: 26759144
[TBL] [Abstract][Full Text] [Related]
17. Recent Developments in the Classification, Evaluation, Pathophysiology, and Management of Scleroderma Renal Crisis.
Ghossein C; Varga J; Fenves AZ
Curr Rheumatol Rep; 2016 Jan; 18(1):5. PubMed ID: 26711696
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic Microangiopathy Secondary to Systemic Sclerosis with Severe Complement Activation Not Responsive to Eculizumab: A Case Report.
Nakamura M; Abe T; Ochiai H
Am J Case Rep; 2022 Jun; 23():e936116. PubMed ID: 35671252
[TBL] [Abstract][Full Text] [Related]
19. [Scleroderma renal crisis].
Teixeira L; Servettaz A; Mehrenberger M; Noël LH; Guillevin L; Mouthon L
Presse Med; 2006 Dec; 35(12 Pt 2):1966-74. PubMed ID: 17159723
[TBL] [Abstract][Full Text] [Related]
20. Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis.
Cole A; Ong VH; Denton CP
Clin Rev Allergy Immunol; 2023 Jun; 64(3):378-391. PubMed ID: 35648373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
